BDTX - CIK 0001701541
The table below shows Black Diamond Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.23M | $53.41M | -$21.20M | -$20.03M | -$28.60M | -$24.45M |
| Capital expenditure | - | - | - | $0.00 | $7.00K | $40.00K |
| Investing cash flow | $19.50M | $8.55M | -$13.73M | $24.81M | $16.73M | $3.47M |
| Dividends paid | - | - | - | - | - |
Black Diamond Therapeutics, Inc. reported operating cash flow of $29.61M for fiscal year 2025. That is up 147.5% from -$62.30M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$8.45M (FY 2018) to $29.61M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$185.00K | $32.00K | $4.13M | $51.00K | $153.00K | $481.00K |